<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292509</url>
  </required_header>
  <id_info>
    <org_study_id>ROKSANA study</org_study_id>
    <nct_id>NCT04292509</nct_id>
  </id_info>
  <brief_title>Risk for Ketonaemia in Type 1 Diabetes Pregnancies With Sensor-augmented Pump Therapy</brief_title>
  <acronym>ROKSANA</acronym>
  <official_title>Risk for Ketonaemia in Type 1 Diabetes Pregnancies With Sensor-augmented Pump Therapy With Predictive Stop Before Low Compared to Stop on Low: an Open-label Crossover RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ROKSANA study is an open-label crossover RCT with the aim to evaluate whether
      sensor-augmented pump therapy (SAP) with predictive low glucose suspend technology is
      associated with an increased risk for ketonaemia during type 1 diabetes pregnancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      10 pregnant women with type 1 diabetes will be included . Participants will be randomized 1/1
      between 12-30 weeks of pregnancy to SAP with predictive stop before low during two weeks or
      predictive stop on low. Participants will be cross-over to the other group after two weeks
      (from stop before low to stop on low or vice versa). During the study, participants will be
      asked to measure blood ketones three times per day.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>open-label cross-over RCT</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood ketones &gt; 0.6mmol/l.</measure>
    <time_frame>4 weeks</time_frame>
    <description>ketonaemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean concentration of blood ketones</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean time of suspension of insulin delivery</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of hospitalization due to ketonaemia</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean glucose based on CGM</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time &gt;140 mg/dl</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time &gt;180 mg/dl</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time &lt;63 mg/dl</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time &lt;50mg/dl</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coefficient of variation of glycaemic measurements</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>standard deviation of glycaemic measurements</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean amplitude of glucose excursions</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time 70-180 mg/dL</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of CGM use &gt;80% of time</measure>
    <time_frame>4 weeks</time_frame>
    <description>CGM compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total insulin dose</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severe hypoglycemic episodes</measure>
    <time_frame>4 weeks</time_frame>
    <description>defined as requiring third-party assistance and/or capillary glucose &lt;50 mg/dL associated with clinical symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pregnant Women With Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>SAP with predictive stop before low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sensor-augmented pump therapy with the use of the predictive stop before low mode of action</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAP with stop on low</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sensor-augmented pump therapy with the use of the predictive stop on low mode of action</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAP with stop before low</intervention_name>
    <description>cross-over comparison from stop on low to stop before low</description>
    <arm_group_label>SAP with predictive stop before low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAP with stop on low</intervention_name>
    <description>cross-over comparison from stop before low to stop on low</description>
    <arm_group_label>SAP with stop on low</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 diabetes

          -  age 18-45 years

          -  a singleton pregnancy with ultrasound-confirmed gestational age between 12- 30 weeks.

          -  treated with 640 insulin pump and have a baseline HbA1c level â‰¤10%.

        Exclusion Criteria:

          -  a physical or psychological disease likely to interfere with the conduct of the study

          -  medications known to interfere with glucose metabolism
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrien Benhalima, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrien Benhalima, MD PhD</last_name>
    <phone>016340614</phone>
    <phone_ext>016340614</phone_ext>
    <email>katrien.benhalima@uzleuven.be</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

